RSS2.0

Combination boosts progression free survival

Thursday, April 19, 2007

LOS ANGELES ? April 19, 2007? A combination of the drugs cetuximab (Erbitux®) and irinotecan (Camptosar® US, Campto® Europe) showed a significant improvement in length of time the patients survived without the cancer progressing compared to irinotecan alone, a new study shows.
From: www.cancerfacts.com

0 comments: